Influenza Vaccine Market: By Product Type (Live, Attenuated, Recombinant), By Route of Administration (Intranasal, Injection), By Type (Monvalent, Trivalent, Quadrivalent), By Distribution Channel (Hospital and Retail Pharmacies, Government Agencies, Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Influenza Vaccine Market size was valued at USD 7.32 billion in 2023 and is poised to grow at a significant CAGR of 6.5% over 2024-2030. The market refers to the industry that encompasses the production, distribution, and sales of vaccines used for preventing influenza, commonly known as the flu. Influenza is a contagious respiratory illness caused by influenza viruses and can lead to severe complications and even death. Vaccination is a crucial preventive measure in reducing the incidence and severity of influenza infections. The influenza vaccine market is diverse, with various players including pharmaceutical companies, biotechnology firms, and government agencies involved in its development and distribution. These entities collaborate to develop and manufacture different types of influenza vaccines, such as trivalent, quadrivalent, and high-dose vaccines, targeting specific strains of the virus. Several trends shape the global influenza vaccine market.

Increased emphasis on improving the effectiveness and coverage of influenza vaccines, especially for high-risk populations like the elderly and individuals with chronic illnesses. This has led to the development of more advanced vaccine technologies and formulations. Additionally, technological advancements in vaccine delivery, such as the development of intranasal and microneedle-based vaccines, are gaining attention for their potential to enhance vaccine coverage and ease of administration. The global influenza vaccine market dynamics are driven by the need to prevent and control influenza infections. It is characterized by diverse players, ongoing technological advancements, and increasing demand for improved vaccine effectiveness and coverage. The market is expected to continue evolving to address emerging challenges and provide better protection against influenza viruses.

Influenza Vaccine Market Key Developments:
  • In February 2023 Sanofi Pasteur and GlaxoSmithKline (GSK) announced a collaboration to develop and commercialize an influenza vaccine that combines their respective quadrivalent live attenuated influenza vaccine (LAIV) platforms. The new vaccine is expected to be available in the United States in the 2023-2024 influenza season.
  • In January 2023 Seqirus and the Bill & Melinda Gates Foundation announced a collaboration to develop and deliver influenza vaccines to children in low- and middle-income countries. The collaboration will focus on developing new and improved influenza vaccines that are more affordable and accessible for children in these countries.

Global Influenza Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.5%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Influenza Vaccine Market Dynamics

Increasing awareness about the importance of influenza vaccination has led to a higher demand for vaccines around the globe. People are now more informed about the benefits of getting vaccinated against the flu, leading to increased uptake of vaccines. Governments and healthcare organizations have played a significant role in promoting vaccination campaigns, emphasizing the prevention of seasonal outbreaks and potential pandemics. This heightened awareness has resulted in a surge in demand for the influenza vaccines market worldwide, as individuals recognize the value of protecting themselves and others from influenza infections.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Influenza Vaccine Market Segmentation

By Product Type
  • Live
  • Attenuated
  • Recombinant
By Route of Administration
  • Intranasal
  • Injection
By Type
  • Monvalent
  • Trivalent
  • Quadrivalent
By Distribution Channel
  • Hospital and Retail Pharmacies
  • Government Agenices
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

Influenza, commonly known as flu, is a contagious respiratory infection or illness caused by influenza viruses. The influenza vaccine protects a person from getting the flu.

The major factor for the growth of the Influenza Vaccine Market is a high prevalence of influenza, an increase in government focuses on immunization programs, emerging vaccines, and technological progress in vaccine administration.

Astrazeneca Plc (Astrazeneca), Biodiem, Csl Limited (Seqirus GmbH), Emergent Biosolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., Glaxosmithkline Plc.

1. Executive Summary
2.  Global Influenza Vaccines Market Introduction 
2.1. Global Influenza Vaccines Market  - Taxonomy
2.2. Global Influenza Vaccines Market  - Definitions
2.2.1. Product Type
2.2.2. Route of Administration
2.2.3. Type
2.2.4. Distribution Channel
2.2.5. Region
3. Global Influenza Vaccines Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
3.6. M&A Activities
3.7. Competition Assessment
3.8. New Product Launches
4. Global Influenza Vaccines Market  By Product Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
4.1. Live
4.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.3. Market Opportunity Analysis 
4.2. Attenuated
4.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.3. Market Opportunity Analysis 
4.3. Recombinant
4.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.3.3. Market Opportunity Analysis 
5. Global Influenza Vaccines Market  By Route of Administration, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
5.1. Intranasal
5 1 1  Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Injection
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6. Global Influenza Vaccines Market  By Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
6.1. Monvalent
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Trivalent
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Quadrivalent
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Influenza Vaccines Market  By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
7.1. Hospital and Retail Pharmacies
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) 
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)  
7.1.3. Market Opportunity Analysis  
7.2. Government Agenices 
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) 
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)  
7.2.3. Market Opportunity Analysis  
7.3. Others 
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) 
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)  
7.3.3. Market Opportunity Analysis  
8.  Global Influenza Vaccines Market  By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Latin America
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. MEA
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
8.6.  Global Influenza Vaccines Market - Opportunity Analysis Index, By Route of Administration, Product Type, Type, Distribution Channel and Region, 2024-2030
9. North America Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
9.1. Product Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1. Live
9.1.2. Attenuated
9.1.3. Recombinant
9.2. Route of Administration Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1. Intranasal
9.2.2. Injection
9.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1. Monvalent
9.3.2. Trivalent
9.3.3. Quadrivalent
9.4. Distribution Channel Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1. Hospital and Retail Pharmacies
9.4.2. Government Agenices
9.4.3. Others
9.5. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.5.1. USA
9.5.2. Canada
10. Europe Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
10.1. Product Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1. Live
10.1.2. Attenuated
10.1.3. Recombinant
10.2. Route of Administration Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1. Intranasal
10.2.2. Injection
10.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1. Monvalent
10.3.2. Trivalent
10.3.3. Quadrivalent
10.4. Distribution Channel Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1. Hospital and Retail Pharmacies
10.4.2. Government Agenices
10.4.3. Others
10.5. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1. Germany
10.5.2. France
10.5.3. Italy
10.5.4. Spain
10.5.5. Rest of Europe
11. Asia Pacific Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
11.1. Product Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1. Live
11.1.2. Attenuated
11.1.3. Recombinant
11.2. Route of Administration Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1. Intranasal
11.2.2. Injection
11.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1. Monvalent
11.3.2. Trivalent
11.3.3. Quadrivalent
11.4. Distribution Channel Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1. Hospital and Retail Pharmacies
11.4.2. Government Agenices
11.4.3. Others
11.5. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1. China
11.5.2. India
11.5.3. Korea
11.5.4. Japan
11.5.5. Rest of APAC
12. Latin America Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
12.1. Product Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1. Live
12.1.2. Attenuated
12.1.3. Recombinant
12.2. Route of Administration Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1. Intranasal
12.2.2. Injection
12.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1. Monvalent
12.3.2. Trivalent
12.3.3. Quadrivalent
12.4. Distribution Channel Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1. Hospital and Retail Pharmacies
12.4.2. Government Agenices
12.4.3. Others
12.5. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Argentina
12.5.4. Rest of LA
13. MEA Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
13.1. Product Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1. Live
13.1.2. Attenuated
13.1.3. Recombinant
13.2. Route of Administration Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1. Intranasal
13.2.2. Injection
13.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1. Monvalent
13.3.2. Trivalent
13.3.3. Quadrivalent
13.4. Distribution Channel Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1. Hospital and Retail Pharmacies
13.4.2. Government Agenices
13.4.3. Others
13.5. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
14.  Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Sanofi
14.2.2. GSK
14.2.3. Serum Institute of India
14.2.4. Abbott
14.2.5. AstraZeneca
14.2.6. Seqirus
14.2.7. Sinovac
14.2.8. Novovax
14.2.9. Pfizer
14.2.10. Moderna
14.2.11. Daiichi Sankyo
14.2.12. CureVac
14.2.13. Ansun Biopharma, Inc.
14.2.14. Medigen Vaccine Biologics Corp
14.2.15. LiteVax BV
14.2.16. ENA Respiratory Pty Ltd
15.  Research Methodology
16.  Key Assumptions and Acronyms
  • Astrazeneca Plc (Astrazeneca)
  • Biodiem
  • Csl Limited (Seqirus GmbH)
  • Emergent Biosolutions
  • Hoffmann-La Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • Glaxosmithkline Plc.
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Novartis Ag
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

Adjacent Markets